As of 2026-04-08, the Relative Valuation of 4D Molecular Therapeutics Inc (FDMT) is (56.17) USD. This relative valuation is based on P/E multiples. With the latest stock price at 10.24 USD, the upside of 4D Molecular Therapeutics Inc based on Relative Valuation is -648.5%.
The range of the Relative Valuation is (50.21) - (58.39) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.3x - 23.1x | 20.2x |
| Forward P/E multiples | 17.0x - 21.3x | 20.7x |
| Fair Price | (50.21) - (58.39) | (56.17) |
| Upside | -590.3% - -670.3% | -648.5% |
| Date | P/E |
| 2026-04-07 | -3.73 |
| 2026-04-06 | -3.62 |
| 2026-04-02 | -3.45 |
| 2026-04-01 | -3.59 |
| 2026-03-31 | -3.39 |
| 2026-03-30 | -3.12 |
| 2026-03-27 | -3.40 |
| 2026-03-26 | -3.71 |
| 2026-03-25 | -3.60 |
| 2026-03-24 | -3.34 |
| 2026-03-23 | -3.36 |
| 2026-03-20 | -3.13 |
| 2026-03-19 | -3.27 |
| 2026-03-18 | -3.12 |
| 2026-03-17 | -3.13 |
| 2026-03-16 | -3.09 |
| 2026-03-13 | -3.03 |
| 2026-03-12 | -3.08 |
| 2026-03-11 | -3.11 |
| 2026-03-10 | -3.23 |
| 2026-03-09 | -3.18 |
| 2026-03-06 | -3.09 |
| 2026-03-05 | -3.15 |
| 2026-03-04 | -3.25 |
| 2026-03-03 | -3.08 |
| 2026-03-02 | -3.40 |
| 2026-02-27 | -3.52 |
| 2026-02-26 | -3.52 |
| 2026-02-25 | -3.61 |
| 2026-02-24 | -3.67 |
| 2026-02-23 | -3.52 |
| 2026-02-20 | -3.28 |
| 2026-02-19 | -3.34 |
| 2026-02-18 | -3.34 |
| 2026-02-17 | -3.45 |
| 2026-02-13 | -3.40 |
| 2026-02-12 | -3.41 |
| 2026-02-11 | -3.37 |
| 2026-02-10 | -3.31 |
| 2026-02-09 | -3.31 |
| 2026-02-06 | -3.27 |
| 2026-02-05 | -3.05 |
| 2026-02-04 | -3.38 |
| 2026-02-03 | -3.46 |
| 2026-02-02 | -3.33 |
| 2026-01-30 | -3.23 |
| 2026-01-29 | -3.27 |
| 2026-01-28 | -3.13 |
| 2026-01-27 | -3.09 |
| 2026-01-26 | -2.90 |